Japan's Ministry To Support Clinical Trial Contract Business
This article was originally published in PharmAsia News
Japan's Ministry of Economy, Trade and Industry began to take measures to support clinical trial contract business. The measures aim to establish a market where research technology and services can be freely exchanged, and to foster an environment where service providers, users and intermediaries can easily participate. According to the ministry, currently in areas of biology and medical device contact services, small- to mid-sized companies who have advanced technology are not benefiting fully from manufacturing on contract for big companies, and an environment where ideas will be protected and technology will be subjectively evaluated is needed. The ministry will organize an expert committee and expects a report due by February 2009. (Click here for more - Japanese language)
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.